H3K27me3 drug

Aliases

histone H3 lysine-27 trimethylation, repressive histone mark H3K27me3

External links

DrugBank · PubChem

No related entities found.

Mentioned in (19)

Papers in which this entity is mentioned.

• Advancing regulatory variant effect prediction with AlphaGenome. (2026)
• Tracing the evolution of single-cell 3D genomes in Kras-driven cancers. (2025)
• Nucleotide Transformer: building and evaluating robust foundation models for human genomics. (2025)
• Transcription start sites experience a high influx of heritable variants fueled by early development. (2025)
• Transient loss of Polycomb components induces an epigenetic cancer fate. (2024)
• A DNA methylation atlas of normal human cell types. (2023)
• Massively parallel reporter perturbation assays uncover temporal regulatory architecture during neural differentiation. (2022)
• Nanopore sequencing technology, bioinformatics and applications. (2021)
• Genetic compensation triggered by mutant mRNA degradation. (2019)
• Super-enhancers: critical roles and therapeutic targets in hematologic malignancies. (2019)
• Universal Patterns of Selection in Cancer and Somatic Tissues. (2017)
• Orthotopic patient-derived xenografts of paediatric solid tumours. (2017)
• Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. (2014)
• EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma. (2014)
• Landscape of transcription in human cells. (2012)
• Novel mutations target distinct subgroups of medulloblastoma. (2012)
• An integrated encyclopedia of DNA elements in the human genome. (2012)
• Computation for ChIP-seq and RNA-seq studies. (2009)
• Model-based analysis of ChIP-Seq (MACS). (2008)

Merged raw entities (3)

All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.